Jubilant Ingrevia Limited — Q3 FY26 earnings call

Call held 5 Feb 2026

Management summary

Jubilant Ingrevia reported stable overall business performance in Q3 FY26 despite softer pricing across all segments, driven by strong volume growth. The company achieved an 8% increase in 9-month EBITDA and maintained Specialty Chemicals margins above 25%. Key milestones include the upcoming commercialization of a major CDMO order and progress in capacity expansion, while navigating pricing pressures in Nutrition and Chemical Intermediates.

Highlights

  • Specialty Chemicals segment continued to fuel growth momentum, delivering revenue expansion and a robust double-digit increase in EBITDA on a year-to-date basis.

  • Nutrition business sustained a healthy trajectory of volume growth across all core products, with highest overall volumes in the last 7 quarters.

  • Overall volume growth of nearly 9% during the quarter helped offset softer pricing across all segments.

  • EBITDA for the 9-month period increased by 8% to INR436 crore.

  • The Board recommended an interim dividend of 250%, translating to INR2.5 per equity share.

  • Net debt-to-EBITDA ratio improved to 0.94x during the quarter compared to 1.24x in Q2 FY26.

  • Expanded opportunity funnel to over 100 active opportunities with a peak annual revenue potential of INR3,500 crore, with 16 molecules confirmed for INR1,400 crore potential.

Concerns

  • Softer pricing across all three segments presented challenges during the quarter.

  • EBITDA for Q3 FY26 stood at INR136 crore, reflecting an 8% year-on-year decline primarily due to lower pricing.

  • Nutrition segment EBITDA declined 10% year-on-year to INR23 crore, with margins trending lower at 11% due to price declines across vitamin B3 and choline.

  • An exceptional expense of INR13 crore, primarily related to provisioning of employee gratuity and leave encashment mandated by New Labour Code amendments, impacted PAT.

Key financials

  1. Revenue ₹1,051 Cr -0.57%YoY
  2. EBITDA ₹136 Cr -8%YoY
  3. EBITDA Margin 13%
  4. PAT (excl. exceptional) ₹60 Cr
  5. PAT (incl. exceptional) ₹47 Cr -31.9%YoY
  6. Overall Volume Growth 9%

What they filed

Q1 FY27: revenue up 25.2%, net profit up 41.3% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue1,045 1,057 1,051 1,038 1,121 +7%1,051 −1%1,179 +12%1,300 +25%
EBITDA124 138 147 142 135 +9%126 −9%163 +11%199 +40%
Net profit59 69 74 75 69 +17%47 −32%86 +16%106 +41%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Segment breakdown

Share of Revenue
₹1,052 Cr Total
  • Specialty Chemicals ₹458 Cr 43.5%
  • Chemical Intermediates ₹393 Cr 37.4%
  • Nutrition, Health and segment business (Nutrition) ₹201 Cr 19.1%

Capital allocation

high confidence
  • Capex ₹500 Cr internal accruals
    • Upcoming CDMO agro plant at Bharuch
    • New multipurpose facility at Gajraula
    We have incurred year-to-date capex of INR366 crore. The majority of this spend was directed towards the upcoming CDMO agro plant at Bharuch and the construction of our new multipurpose facility at Gajraula. These investments were largely funded through internal accruals. Looking ahead, we plan to invest approximately INR500 crore in 2027, which will also be supported by internal accruals.
  • Debt 0.9× EBITDA
    Consequently, the net debt-to-EBITDA ratio improved to 0.94x during the quarter compared to 1.24x in quarter 2 financial year '26 based on trailing 12 months EBITDA.
  • Dividend ₹2.5/share (interim)
    We are pleased to announce that the Board has recommended an interim dividend of 250%, translating to INR2.5 per equity share.
  • Liquidity Liquidity disclosed Capex largely funded through internal accruals.
    These investments were largely funded through internal accruals.

Guidance & targets

Profitability

  • EBITDA CAGR Profitability · multi-year average · Medium confidence at least 20%
    Too early, but I think we have given a multiyear guidance anyway in last year also that we hope to continue to grow if you take a multiyear average, our EBITDA at least at 20% CAGR. So that is the trajectory.

    — Deepak Jain

  • Specialty Chemical EBITDA Margin Profitability · future · Medium confidence better than 25%
    I think we should hopefully be able to do better than 25% in Specialty Chemical.

    — Deepak Jain

  • New Projects EBITDA Margin Threshold Profitability · new projects · High confidence at least 20%
    So Avnish, the first part of your question, as we have been consistently saying, every new project, every new capex that we take in our company, we keep at least a threshold margin of 20% EBITDA and ROCE of 20% plus.

    — Deepak Jain

  • New Projects ROCE Threshold Profitability · new projects · High confidence at least 20%

    — Deepak Jain

  • Full Year FY26 EBITDA Profitability · FY26 · Medium confidence higher than 8% increase
    Just to add to it, Deepak, Varun here, Abhijit, if you see our 9 months, we have delivered an 8% increase in the EBITDA overall. And as Deepak mentioned, for the full year, we expect it to be higher than that, yes. So if that gives you a certain outlook for the quarter 4.

    — Varun Gupta

What to watch in Q4 FY26

Agrochemical innovator project dispatch

next quarter
Current Plant commissioned, first batch produced, dispatch expected mid-late March 2026
Target Commercial dispatches commenced and revenue contribution visible

Why it matters

This is a major CDMO contract expected to significantly accelerate growth in the CDMO segment.

During the quarter, we also commenced construction of a new multipurpose plant at Gajraula, which will add significant flexibility and capacity to our CDMO and fine chemicals portfolio. Given the progress across our strategic initiatives, we remain confident in sustaining the expected growth trajectory in both top line and margins over the next few quarters.

Risks & concerns

  • Softer pricing across all segments

    medium

    Softer pricing across Specialty Chemicals, Nutrition, and Chemical Intermediates impacted Q3 FY26 EBITDA.

    Management acknowledged

  • Supply-demand imbalance in agrochemical sector

    medium

    Persists, exerting short-term price pressures, though expected to ease in coming quarters.

    Management acknowledged

  • Global competition and price pressure in Nutrition (Vitamin B3)

    medium

    Intensified global competition placed pressure on prices for feed-grade vitamin B3, leading to margin decline.

    Management acknowledged

  • Weak demand and plant closures in Europe for Chemical Intermediates

    medium

    Europe continues to face headwinds, weighing on the segment's performance.

    Management acknowledged

  • Impact of Indian Labour Code amendments

    low

    Resulted in a one-time exceptional expense of INR13 crore for employee gratuity and leave encashment provisioning.

    Management acknowledged

Q&A highlights

8 direct
Pricing pressure across segments (pyridine, B3, acetyls) Direct
So if you look at our specialty business, particularly on the pyridine and its derivatives, the pricing pressure has come in the last 2 quarters... And real big impact of that has been on the last quarter results... we are already seeing some uptick in pricing in certain derivatives... In the nutrition, particularly the vitamin B3... we have seen almost a 7% to 8% increase in price... Acetyl is a different story... we have seen already an uptick in acetic acid price, which we are hoping will gradually start to translate into our acetic anhydride and ethyl acetate prices as well.

Addresses the primary reason for EBITDA decline and provides outlook on recovery for key product categories.

Asked by Archit Joshi

CDMO pipeline and peak potential realization timeline Direct
I think from a pipeline perspective, we talked about this 100-plus opportunities with a peak potential of about INR3,500 crore... the peak potential takes at least 3 years, if not more... what we announced in the last quarterly investor call was about 10 or 11 molecules with a peak potential of INR1,200 crore. In last 3 months... we have added another 5 molecules and then the peak potential has reached almost INR1,400 crore plus.

Clarifies the scale and timeline for the significant CDMO growth pipeline, distinguishing between confirmed wins and overall funnel.

Asked by Archit Joshi

Agrochemical intermediate project deliveries and FY26/FY27 impact Direct
On the first question, we remain pretty much on track... the plant is ready... the first output, a lot of output will come within this quarter... we are hoping that the first few months, which is what we are gearing towards and planning to start supplies of that hopefully by mid and late March this year.

Provides concrete timeline for the commercialization of a major CDMO project, indicating revenue contribution starting in Q4 FY26.

Asked by Abhijit Akella

Minimum offtake commitments and volume visibility for CDMO contracts Direct
Nitesh, we never disclose the names of our CDMO molecules or customers publicly... our CDMO contracts and the delivery against what we have agreed with the customer stays on track and we do not see any lack of visibility there. At least for the first few months, even for the big contract, we have already gotten visibility from the customer, and we are planning to start dispatching late March.

Reassures on the contractual security and volume visibility for CDMO projects, addressing potential risks of demand fluctuations.

Asked by Nitesh Dhoot

India-EU FTA benefits and specific product areas Direct
On the EU side also, right now, there is duty or tariff of about 6% to 7% for a bunch of our products like it is for China as well. As those duties go away next year, hopefully, our level of competitiveness will increase, which we are hoping to leverage to get some volume and hopefully even price upside starting next year... one example, by the way, is the choline where as soon as we had a favorable tariff structure vis-a-vis the Chinese competition, our share has already started to increase and we have started to book volumes in European market.

Highlights specific market opportunities and products (like choline) that could benefit from the FTA, improving competitiveness against Chinese suppliers.

Asked by Nitesh Dhoot

Profitability of large agrochemical CDMO order and margin rationale Direct
every new project, every new capex that we take in our company, we keep at least a threshold margin of 20% EBITDA and ROCE of 20% plus. So the same is true for this project also... this product is a generic product. And obviously, we have to ultimately, the key principle behind a CDMO business is also to support the customer to be competitive in the market... in the agro segment within CDMO, margin for most players will be between 20% and 25%.

Explains the margin profile of the large CDMO order, clarifying that while it meets internal thresholds, it's a generic product, hence margins are in the 20-25% range typical for agro CDMO.

Asked by Avnish Burman

Nutrition & Health margins improvement timeline and mix shift Direct
the impact of price decline in feed segment... has kind of offset the positive impact coming from cosmetic and food segment growth... we have seen price uptick in feed as well... the combined impact of both of these should hopefully start reflecting in this quarter and definitely next quarter onwards.

Provides a timeline for expected margin recovery in the Nutrition segment, driven by price upticks in feed and continued growth in higher-margin cosmetic/food products.

Asked by Gokul Maheshwari

Agrochemical CDMO contract delay from January to March Direct
I think we always maintained we will start the production process, the plant in January, so which is what we did. 5th of January, we did the puja at the plant and commissioned the first batch. It is a complex multistage product. So the whole cycle of producing even the first kg of final product is at least a six to eight weeks process... So there is no delay or delay of production or even on placement of the order from the customer. It is just a process.

Clarifies that the perceived delay is due to the multi-stage production process of a complex molecule, not a delay in plant readiness or customer orders, maintaining confidence in the project timeline.

Asked by Atishray Malhan

3 min read 7 chapters

Detailed narrative

Overall Business Performance and Volume Growth

Jubilant Ingrevia reported stable overall business performance in Q3 FY26, with revenue at INR1,051 crore, slightly down from INR1,057 crore in Q3 FY25. Despite macroeconomic headwinds and softer pricing across all three segments, the company achieved nearly 9% volume growth during the quarter. For the 9-month period, revenue increased by 3% and EBITDA rose by 8% to INR436 crore, demonstrating resilience.

Specialty Chemicals Segment Drives Growth

The Specialty Chemicals segment continued to be a key growth driver, delivering revenue of INR458 crore in Q3 FY26. The segment maintained robust EBITDA margins above 25%, with absolute EBITDA at INR116 crore. On a 9-month basis, Specialty Chemicals revenue grew 7% to INR1,421 crore, and EBITDA surged 27% to INR371 crore, with margins remaining above 26%. This performance was supported by a favorable product mix and ongoing cost optimization initiatives.

Nutrition Business Sustains Volume, Faces Pricing Headwinds

The Nutrition business recorded INR201 crore in revenue for Q3 FY26, a 6% year-on-year increase, driven by healthy volume growth across core products, reaching its highest overall volumes in the past 7 quarters. However, segment EBITDA declined 10% year-on-year to INR23 crore, with margins trending lower at 11% due to price declines in vitamin B3 and choline. Margins are expected to improve in coming quarters as prices recover and the share of cosmetic and food-grade products increases.

Chemical Intermediates Navigates Pricing Pressure

The Chemical Intermediates segment reported revenue of INR393 crore in Q3 FY26, slightly down from INR400 crore in Q3 FY25. The segment maintained its market share and recorded year-on-year volume growth. Pricing contraction and the pass-through of lower raw material costs in an oversupplied market impacted EBITDA. The company continues to advance cost initiatives to absorb these impacts, with an uptick in acetic acid prices expected to translate into better realizations for acetic anhydride and ethyl acetate.

CDMO and Growth Pipeline Expansion

Jubilant Ingrevia is making significant progress in its CDMO business, with an expanded opportunity funnel of over 100 active opportunities representing a peak annual revenue potential of INR3,500 crore. Over the past year, 16 molecules have been confirmed with an estimated peak potential of INR1,400 crore. The company is on track to commence delivery of a major CDMO order in Q4 FY26, and construction has begun on a new multipurpose plant in Gajraula to strengthen capacity for CDMO and fine chemicals.

Capital Expenditure and Operational Efficiency

The company incurred INR366 crore in capex year-to-date, primarily for the CDMO agro plant at Bharuch and the new multipurpose facility at Gajraula, funded through internal accruals. Approximately INR500 crore is planned for capex in FY27, also to be supported by internal accruals. A new boiler was commissioned at the Bharuch site, enhancing operational efficiency. Renewable power share increased to 34% in Q3, up from 28% in Q2, contributing to a 10% year-on-year reduction in fuel expenses.

Market Dynamics and Pricing Outlook

Across the broader chemical industry, volumes are recovering, but pricing pressure persists. In the pharmaceutical end-use market, volumes remained steady, particularly in fine chemicals. The agrochemical sector is seeing recovery in volumes, though demand-supply imbalance still affects prices. Niacinamide demand remains strong, but pricing is under strain. Management anticipates pricing to bottom out and expects a gradual recovery across segments, with some uptick already observed in pyridine derivatives, vitamin B3, and acetic acid.

This is an AI-generated summary of a publicly available earnings call transcript.
View original transcript

More Chemicals earnings calls